Literature DB >> 9637135

Herceptin raises its sights beyond advanced breast cancer.

C McNeil.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637135     DOI: 10.1093/jnci/90.12.882

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

Review 1.  Abrogation of transforming growth factor-beta signaling in pancreatic cancer.

Authors:  Xia Lin; Xin-Hua Feng
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

Review 2.  Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

Authors:  P Nagy; A Jenei; S Damjanovich; T M Jovin; J Szölôsi
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 3.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

4.  Decoding human liver cancer signatures.

Authors:  Ju-Seog Lee
Journal:  Gastrointest Cancer Res       Date:  2008-07

5.  Heregulin β-1 induces loss of cell-cell contact and enhances expression of MUC1 at the cell surface in HCC2998 and MKN45-1 cells.

Authors:  Rintaro Okoshi; Chung-Li Shu; Sayoko Ihara; Yasuhisa Fukui
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

6.  Scattering of MCF7 cells by heregulin ß-1 depends on the MEK and p38 MAP kinase pathway.

Authors:  Rintaro Okoshi; Chung-Li Shu; Sayoko Ihara; Yasuhisa Fukui
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.